Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Z

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are More Effective and Tolerated, Interferon Alfa Not Recommended for Cutaneous Disease, & What Therapy in BRAF Mutant Disease

By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Skin
14:32
Xth Eurasian Hematology-Oncology Congress

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Feat. Z. Turna
06:35
Xth Eurasian Hematology-Oncology Congress

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Feat. Z. Turna
21:19
Xth Eurasian Hematology-Oncology Congress

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Feat. S. Seber
05:25
Xth Eurasian Hematology-Oncology Congress

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Feat. D. Erdem
15:44
Xth Eurasian Hematology-Oncology Congress

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Feat. D. Erdem